LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 53

Search options

  1. Article ; Online: Cytokines as predictors of COVID-19 severity: evidence from a meta-analysis. Authors' reply.

    Kosmaczewska, Agata / Frydecka, Irena

    Polish archives of internal medicine

    2021  Volume 131, Issue 1, Page(s) 99–100

    MeSH term(s) COVID-19 ; Cytokines ; Humans ; SARS-CoV-2
    Chemical Substances Cytokines
    Language English
    Publishing date 2021-01-29
    Publishing country Poland
    Document type Letter ; Comment
    ZDB-ID 123500-x
    ISSN 1897-9483 ; 0032-3772
    ISSN (online) 1897-9483
    ISSN 0032-3772
    DOI 10.20452/pamw.15793
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Are patients with lung cystic fibrosis at increased risk of severe and fatal COVID-19? Interleukin 6 as a predictor of COVID-19 outcomes. Authors' reply.

    Kosmaczewska, Agata / Frydecka, Irena

    Polish archives of internal medicine

    2020  Volume 130, Issue 10, Page(s) 920–921

    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus ; Coronavirus Infections ; Cystic Fibrosis ; Humans ; Immune System ; Interleukin-6 ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2
    Chemical Substances Interleukin-6
    Keywords covid19
    Language English
    Publishing date 2020-10-29
    Publishing country Poland
    Document type Letter ; Comment
    ZDB-ID 123500-x
    ISSN 1897-9483 ; 0032-3772
    ISSN (online) 1897-9483
    ISSN 0032-3772
    DOI 10.20452/pamw.15660
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Dysregulation of the immune system as a driver of the critical course of novel coronavirus disease 2019.

    Kosmaczewska, Agata / Frydecka, Irena

    Polish archives of internal medicine

    2020  Volume 130, Issue 9, Page(s) 779–788

    Abstract: Novel coronavirus disease 2019 (COVID‑19) is a highly contagious, respiratory disease caused by the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). Given that inflammatory immune cells may induce severe lung injury, the ... ...

    Abstract Novel coronavirus disease 2019 (COVID‑19) is a highly contagious, respiratory disease caused by the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2). Given that inflammatory immune cells may induce severe lung injury, the involvement of immunological factors in the pathogenesis of the disease cannot be overestimated. It has been demonstrated that coronaviruses have developed mechanisms of immune evasion, making themselves invisible to the immune system at an early stage of infection. The mechanism relies on inhibiting the antiviral response of type I interferons, which enhances uncontrolled viral replication in epithelial cells. There has been a growing body of evidence showing that fatal hyperinflammation (cytokine storm) responsible for the severe course of COVID‑19 is a consequence of massive SARS‑CoV‑2 replication rather than inappropriate hyperresponsiveness of the immune system. Therefore, the suppressed antiviral innate immune response seems to be the primary cause of the delayed critical cascade of uncontrolled immune events leading to fulminant systemic inflammation. The occurrence of virus transmission even in asymptomatic individuals infected with SARS‑CoV‑2 clearly strengthens the evidence for the key role played by the sufficient immune control of viral replication in a subset of cases (eg, in children, a population with a highly effective innate immune response). Although administration of immunomodulatory drugs is recommended under certain conditions by the guidelines for COVID‑19 management, controversies regarding treatment protocols in immunocompromised patients infected with SARS‑CoV‑2 still exist. Extending clinicians' knowledge on the dysregulated immune response, which is a driver of the COVID‑19 outcome, may improve both therapeutic strategies and the prognosis of patients infected with SARS‑CoV‑2.
    MeSH term(s) COVID-19 ; Coronavirus Infections/immunology ; Cytokines/immunology ; Female ; Humans ; Immune System/immunology ; Immunity, Innate ; Inflammation ; Male ; Pandemics ; Pneumonia, Viral/immunology
    Chemical Substances Cytokines
    Keywords covid19
    Language English
    Publishing date 2020-07-06
    Publishing country Poland
    Document type Journal Article ; Review
    ZDB-ID 123500-x
    ISSN 1897-9483 ; 0032-3772
    ISSN (online) 1897-9483
    ISSN 0032-3772
    DOI 10.20452/pamw.15482
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity.

    Kosmaczewska, Agata

    International journal of molecular sciences

    2014  Volume 15, Issue 10, Page(s) 18574–18592

    Abstract: For many years, the role of interleukin-2 (IL-2) in autoimmune responses was established as a cytokine possessing strong pro-inflammatory activity. Studies of the past few years have changed our knowledge on IL-2 in autoimmune chronic inflammation, ... ...

    Abstract For many years, the role of interleukin-2 (IL-2) in autoimmune responses was established as a cytokine possessing strong pro-inflammatory activity. Studies of the past few years have changed our knowledge on IL-2 in autoimmune chronic inflammation, suggesting its protective role, when administered at low-doses. The disrupted balance between regulatory and effector T cells (Tregs and Teffs, respectively) is a characteristic of autoimmune diseases, and is dependent on homeostatic cytokines, including IL-2. Actually, inherent defects in the IL-2 signaling pathway and/or levels leading to Treg compromised function and numbers as well as Th17 expansion have been attributed to autoimmune disorders. In this review, we discuss the role of IL-2 in the pathogenesis of autoimmune diseases. In particular, we highlight the impact of the dysregulated IL-2 pathway on disruption of the Treg/Th17 balance, reversal of which appears to be a possible mechanism of the low-dose IL-2 treatment. The negative effects of IL-2 on the differentiation of follicular helper T cells (Tfh) and pathogenic Th17 cells, both of which contribute to autoimmunity, is emphasized in the paper as well. We also compare the current IL-2-based therapies of animal and human subjects with immune-mediated diseases aimed at boosting the Treg population, which is the most IL-2-dependent cell subset desirable for sufficient control of autoimmunity. New perspectives of therapeutic approaches focused on selective delivery of IL-2 to inflamed tissues, thus allowing local activity of IL-2 to be combined with its reduced systemic and pleiotropic toxicity, are also proposed in this paper.
    MeSH term(s) Animals ; Autoimmune Diseases/immunology ; Autoimmune Diseases/pathology ; Autoimmune Diseases/therapy ; Autoimmunity ; Humans ; Immune Tolerance ; Immunotherapy/methods ; Interleukin-2/administration & dosage ; Interleukin-2/immunology ; Interleukin-2/therapeutic use ; Signal Transduction ; T-Lymphocytes, Regulatory/immunology ; T-Lymphocytes, Regulatory/pathology ; Th17 Cells/immunology ; Th17 Cells/pathology
    Chemical Substances Interleukin-2
    Language English
    Publishing date 2014-10-15
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms151018574
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Are patients with lung cystic fibrosis at increased risk of severe and fatal COVID-19? Interleukin 6 as a predictor of COVID-19 outcomes. Authors' reply

    Kosmaczewska, Agata / Frydecka, Irena

    Pol Arch Intern Med

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #895813
    Database COVID19

    Kategorien

  6. Article ; Online: Low-Dose Interleukin-2 Therapy

    Agata Kosmaczewska

    International Journal of Molecular Sciences, Vol 15, Iss 10, Pp 18574-

    A Driver of an Imbalance between Immune Tolerance and Autoimmunity

    2014  Volume 18592

    Abstract: For many years, the role of interleukin-2 (IL-2) in autoimmune responses was established as a cytokine possessing strong pro-inflammatory activity. Studies of the past few years have changed our knowledge on IL-2 in autoimmune chronic inflammation, ... ...

    Abstract For many years, the role of interleukin-2 (IL-2) in autoimmune responses was established as a cytokine possessing strong pro-inflammatory activity. Studies of the past few years have changed our knowledge on IL-2 in autoimmune chronic inflammation, suggesting its protective role, when administered at low-doses. The disrupted balance between regulatory and effector T cells (Tregs and Teffs, respectively) is a characteristic of autoimmune diseases, and is dependent on homeostatic cytokines, including IL-2. Actually, inherent defects in the IL-2 signaling pathway and/or levels leading to Treg compromised function and numbers as well as Th17 expansion have been attributed to autoimmune disorders. In this review, we discuss the role of IL-2 in the pathogenesis of autoimmune diseases. In particular, we highlight the impact of the dysregulated IL-2 pathway on disruption of the Treg/Th17 balance, reversal of which appears to be a possible mechanism of the low-dose IL-2 treatment. The negative effects of IL-2 on the differentiation of follicular helper T cells (Tfh) and pathogenic Th17 cells, both of which contribute to autoimmunity, is emphasized in the paper as well. We also compare the current IL-2-based therapies of animal and human subjects with immune-mediated diseases aimed at boosting the Treg population, which is the most IL-2-dependent cell subset desirable for sufficient control of autoimmunity. New perspectives of therapeutic approaches focused on selective delivery of IL-2 to inflamed tissues, thus allowing local activity of IL-2 to be combined with its reduced systemic and pleiotropic toxicity, are also proposed in this paper.
    Keywords interleukin-2 ; immunotherapy ; immune-mediated disease ; autoimmunity ; immune tolerance ; clinical trial ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Subject code 610
    Language English
    Publishing date 2014-10-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article: Dysregulation of the immune system as a driver of the critical course of novel coronavirus disease 2019

    Kosmaczewska, Agata / Frydecka, Irena

    Pol Arch Intern Med

    Abstract: Novel coronavirus disease 2019 (COVID­19) is a highly contagious, respiratory disease caused by the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS­CoV­2). Given that inflammatory immune cells may induce severe lung injury, the ... ...

    Abstract Novel coronavirus disease 2019 (COVID­19) is a highly contagious, respiratory disease caused by the newly emerged severe acute respiratory syndrome coronavirus 2 (SARS­CoV­2). Given that inflammatory immune cells may induce severe lung injury, the involvement of immunological factors in the pathogenesis of the disease cannot be overestimated. It has been demonstrated that coronaviruses have developed mechanisms of immune evasion, making themselves invisible to the immune system at an early stage of infection. The mechanism relies on inhibiting the antiviral response of type I interferons, which enhances uncontrolled viral replication in epithelial cells. There has been a growing body of evidence showing that fatal hyperinflammation (cytokine storm) responsible for the severe course of COVID­19 is a consequence of massive SARS­CoV­2 replication rather than inappropriate hyperresponsiveness of the immune system. Therefore, the suppressed antiviral innate immune response seems to be the primary cause of the delayed critical cascade of uncontrolled immune events leading to fulminant systemic inflammation. The occurrence of virus transmission even in asymptomatic individuals infected with SARS­CoV­2 clearly strengthens the evidence for the key role played by the sufficient immune control of viral replication in a subset of cases (eg, in children, a population with a highly effective innate immune response). Although administration of immunomodulatory drugs is recommended under certain conditions by the guidelines for COVID­19 management, controversies regarding treatment protocols in immunocompromised patients infected with SARS­CoV­2 still exist. Extending clinicians' knowledge on the dysregulated immune response, which is a driver of the COVID­19 outcome, may improve both therapeutic strategies and the prognosis of patients infected with SARS­CoV­2.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #634302
    Database COVID19

    Kategorien

  8. Article ; Online: Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors.

    Kulikowska de Nałęcz, Anna / Ciszak, Lidia / Usnarska-Zubkiewicz, Lidia / Pawlak, Edyta / Frydecka, Irena / Szmyrka, Magdalena / Kosmaczewska, Agata

    International journal of molecular sciences

    2023  Volume 24, Issue 6

    Abstract: Multiple myeloma (MM) is a hematologic malignancy characterized by severely profound immune dysfunction. Therefore, the efficacy of drugs targeting the immune environments, such as immune checkpoint inhibitors (ICIs), is of high clinical importance. ... ...

    Abstract Multiple myeloma (MM) is a hematologic malignancy characterized by severely profound immune dysfunction. Therefore, the efficacy of drugs targeting the immune environments, such as immune checkpoint inhibitors (ICIs), is of high clinical importance. However, several clinical trials evaluating ICIs in MM in different therapeutic combinations revealed underwhelming results showing a lack of clinical efficacy and excessive side effects. The underlying mechanisms of resistance to ICIs observed in the majority of MM patients are still under investigation. Recently, we demonstrated that inappropriate expression of PD-1 and CTLA-4 on CD4 T cells in active MM is associated with adverse clinical outcomes and treatment status. The aim of the current study was to determine the usefulness of immune checkpoint expression assessment as a predictive biomarker of the response to therapeutic inhibitors. For this purpose, along with checkpoint expression estimated by flow cytometry, we evaluated the time to progression (TTP) of MM patients at different clinical stages (disease diagnosis and relapse) depending on the checkpoint expression level; the cut-off point (dividing patients into low and high expressors) was selected based on the median value. Herein, we confirmed the defective levels of regulatory PD-1, CTLA-4 receptors, and the CD69 marker activation in newly diagnosed (ND) patients, whereas relapsed/refractory patients (RR) exhibited their recovered values and reactivity. Additionally, substantially higher populations of senescent CD4
    MeSH term(s) Humans ; CTLA-4 Antigen ; Multiple Myeloma/diagnosis ; Multiple Myeloma/drug therapy ; Multiple Myeloma/genetics ; Programmed Cell Death 1 Receptor ; Neoplasm Recurrence, Local/etiology ; Immunotherapy/methods
    Chemical Substances CTLA-4 Antigen ; Programmed Cell Death 1 Receptor
    Language English
    Publishing date 2023-03-17
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms24065730
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Archaeobotanical evidence and ethnobotanical interpretation of plants used as coffin pillow fillings in burials in Poland (17th-18/19th centuries)

    Badura, Monika / Jarosińska, Marta / Noryśkiewicz, Agnieszka M. / Kosmaczewska, Agata / Sady-Bugajska, Agata / Święta-Musznicka, Joanna / Pińska, Katarzyna / Latałowa, Małgorzata

    Veget Hist Archaeobot. 2023 Jan., v. 32, no. 1 p.85-103

    2023  

    Abstract: The aim of this article is the study of the botanical material in the fillings of 54 coffin pillows from Catholic and Protestant burials dated to the 17th-18/19th centuries, collected during the investigation of 15 church crypts in different regions of ... ...

    Abstract The aim of this article is the study of the botanical material in the fillings of 54 coffin pillows from Catholic and Protestant burials dated to the 17th-18/19th centuries, collected during the investigation of 15 church crypts in different regions of Poland, and consideration of the role of the plants used for this purpose. In a large part of the dataset, a comprehensive picture of the botanical composition of the pillow fills has been obtained through the parallel studies of plant macroremains and pollen. Advantages and pitfalls in the use of pollen analysis on these specific remains are discussed. The results show that a large number of taxa were used in pillow fillings. The choice of plants was mostly dictated by their aromatic, insect repellent and preservative properties as well as their symbolic meanings, but the morphology and other physical properties of plants used in the fillings was also of importance. In some cases, the use of plants from bouquets which had been blessed in specific Catholic church ceremonies is suggested. The possible season of burial according to the botanical composition of the pillows is discussed.
    Keywords archaeobotany ; botanical composition ; data collection ; insect repellents ; pollen ; pollen analysis ; Poland
    Language English
    Dates of publication 2023-01
    Size p. 85-103.
    Publishing place Springer Berlin Heidelberg
    Document type Article ; Online
    ZDB-ID 1481434-1
    ISSN 1617-6278 ; 0939-6314
    ISSN (online) 1617-6278
    ISSN 0939-6314
    DOI 10.1007/s00334-022-00884-z
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  10. Article ; Online: Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis

    Anna Kulikowska de Nałęcz / Lidia Ciszak / Lidia Usnarska-Zubkiewicz / Edyta Pawlak / Irena Frydecka / Magdalena Szmyrka / Agata Kosmaczewska

    International Journal of Molecular Sciences, Vol 24, Iss 5730, p

    Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors

    2023  Volume 5730

    Abstract: Multiple myeloma (MM) is a hematologic malignancy characterized by severely profound immune dysfunction. Therefore, the efficacy of drugs targeting the immune environments, such as immune checkpoint inhibitors (ICIs), is of high clinical importance. ... ...

    Abstract Multiple myeloma (MM) is a hematologic malignancy characterized by severely profound immune dysfunction. Therefore, the efficacy of drugs targeting the immune environments, such as immune checkpoint inhibitors (ICIs), is of high clinical importance. However, several clinical trials evaluating ICIs in MM in different therapeutic combinations revealed underwhelming results showing a lack of clinical efficacy and excessive side effects. The underlying mechanisms of resistance to ICIs observed in the majority of MM patients are still under investigation. Recently, we demonstrated that inappropriate expression of PD-1 and CTLA-4 on CD4 T cells in active MM is associated with adverse clinical outcomes and treatment status. The aim of the current study was to determine the usefulness of immune checkpoint expression assessment as a predictive biomarker of the response to therapeutic inhibitors. For this purpose, along with checkpoint expression estimated by flow cytometry, we evaluated the time to progression (TTP) of MM patients at different clinical stages (disease diagnosis and relapse) depending on the checkpoint expression level; the cut-off point (dividing patients into low and high expressors) was selected based on the median value. Herein, we confirmed the defective levels of regulatory PD-1, CTLA-4 receptors, and the CD69 marker activation in newly diagnosed (ND) patients, whereas relapsed/refractory patients (RR) exhibited their recovered values and reactivity. Additionally, substantially higher populations of senescent CD4 + CD28 − T cells were found in MM, primarily in NDMM subjects. These observations suggest the existence of two dysfunctional states in MM CD4 T cells with the predominance of immunosenescence at disease diagnosis and exhaustion at relapse, thus implying different responsiveness to the external receptor blockade depending on the disease stage. Furthermore, we found that lower CTLA-4 levels in NDMM patients or higher PD-1 expression in RRMM patients may predict early relapse. In conclusion, ...
    Keywords multiple myeloma ; PD-1 ; CTLA-4 ; immune checkpoint inhibitors ; time to progression ; clinical response ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Subject code 610
    Language English
    Publishing date 2023-03-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top